Insight Molecular Diagnostics Inc. (IMDX)
NASDAQ: IMDX · Real-Time Price · USD
3.190
-0.180 (-5.34%)
At close: Jun 27, 2025, 4:00 PM
3.160
-0.030 (-0.94%)
After-hours: Jun 27, 2025, 7:14 PM EDT

Company Description

Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally.

The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests.

It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies.

The company also offers VitaGraft Kidney, a blood-based transplant monitoring test that quantifies the concentration of donor-derived cell-free DNA for kidney transplantation; VitaGraft Liver, a blood-based transplant monitoring test that quantifies the concentration of donor-derived cell-free DNA for liver transplantation; and GraftAssure, a dd-cfDNA test that uses droplet digital PCR technology to measure the concentration of dd-cfDNA using 48 predefined SNPs.

In addition, it provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests.

The company has a collaboration agreement with Bio-Rad Laboratories, Inc. for the development and commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad’s ddPCR instruments and reagents.

Insight Molecular Diagnostics Inc. was formerly known as OncoCyte Corporation and changed its name to Insight Molecular Diagnostics Inc. in June 2025.

Insight Molecular Diagnostics Inc. was incorporated in 2009 and is based in Irvine, California.

Insight Molecular Diagnostics Inc.
Insight Molecular Diagnostics logo
Country United States
Founded 2009
Industry Diagnostics & Research
Sector Healthcare
Employees 49
CEO Joshua Riggs

Contact Details

Address:
2 International Plaza Dr., Suite 510
Nashville, Tennessee 37217
United States
Phone 949 409 7600
Website imdxinc.com

Stock Details

Ticker Symbol IMDX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001642380
CUSIP Number 68235C206

Key Executives

Name Position
Joshua Riggs Chief Executive Officer
Andrea James Chief Financial Officer